leadf
logo-loader
viewBioLargo, Inc.

BioLargo completes prototype for PFAS treatment system, ready for pilot testing

BioLargo (OTCQB: BLGO) CEO Dennis Calvert Calvert joined Steve Darling from Proactive with news the company has completed manufacturing on its first prototype unit of their patented BioLargo AEC to tackle PFAS contamination.

Calvert told Proactive the next step and he also told investors about a new product from their Clyra Medical called Clyraguard.

Quick facts: BioLargo, Inc.

Price: 0.13545 USD

OTCMKTS:BLGO
Market: OTCQB
Market Cap: $28.93 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BioLargo, Inc. named herein, including the promotion by the Company of BioLargo, Inc. in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

BioLargo awarded contract at major chemical manufacturing plant for...

BioLargo (OTCQB: BLGO) CEO Dennis Calvert joined Steve Darling from Proactive Vancouver with news the company’s subsidiary BioLargo Engineering, Science & Technologies has been awarded a contract to assist in the reconfiguration of the Regenerative Thermal Oxidizer systems used at a large...

5 days, 19 hours ago

2 min read